Treatment of agitation associated with Alzheimer's disease with a combination of bupropion and dextromethorphan

A method of treating agitation associated with Alzheimer's disease in a human patient having agitation associated with Alzheimer's disease comprising:

• 1) orally administering a first dosage form once daily for one week to the human patient, then administering the first dosage form twice daily to the human patient for one week;
• and 2) then orally administering a second dosage form twice daily to the human patient for at least one week;
• wherein the human patient has mild or moderate hepatic impairment;
• wherein the first dosage form comprises about 30 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan, about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion, and a polymer;
• wherein the second dosage form comprises about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another salt form of dextromethorphan or the free base form of dextromethorphan, and about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another salt form of bupropion or the free base form of bupropion;
• and
• wherein the first and second dosage forms are bilayertablets, wherein the bupropion and the dextromethorphan in each of the tablets are in separate layers.